38 39 Background: Deposition of complement factors on Mycobacterium leprae 40 may enhance phagocytosis. Such deposition may occur through the lectin 41 pathway of complement. Three proteins of the lectin pathway are produced 42 from the gene MASP1: Mannan-binding lectin-associated serine protease 1 43 (MASP-1) and MASP-3 and mannan-binding lectin-associated protein of 44 44 kDa (MAp44). Despite their obvious importance, the roles played by these 45 proteins have never been investigated in leprosy disease. Methodology: We 46 haplotyped five MASP1 polymorphisms by multiplex sequence-specific PCR 47 (intronic rs7609662*G>A and rs13064994*C>T, exon 12 3'-untranslated 48 rs72549262*C>G, rs1109452*C>T and rs850314*G>A) and measured 49 MASP-1, MASP-3 and MAp44 serum levels in 196 leprosy patients (60%, 50 lepromatous) and 193 controls. Principal findings: Lower MASP-3 and 51 MAp44 levels were observed in patients, compared with controls (P=0.0002
189 polymorphisms of the CR1 gene associated with leprosy, as well as a 190 negative correlation between the anti-inflammatory soluble CR1 and pro-191 inflammatory MBL levels, probably preventing inflammation (10) .
192
Given this context, we investigated whether MASP1 gene variants and 193 products are associated with susceptibility to leprosy and to the different 194 clinical forms of the disease. We aim at providing a better understanding of 210 Patients were diagnosed based on clinical and histopathological features and 211 classified according to Ridley and Jopling criteria (40) . The control group 212 comprised of 214 blood donors from the Hemepar and HC-UFPR blood banks 213 and were from the same socioeconomic, ethnic and geographic background.
214 Patients and controls were defined as Euro-, Afro-Brazilians or Amerindians, 215 based on physical characteristics and ancestry information. This means 9%
216 and 5% average sub-Saharan African and Amerindian ancestry respectively, 217 for the former, and at least 40% of African and 6% of Amerindian ancestry for 218 the latter, based on HLA genotyping for South Brazilian populations classified 219 in the same way (41) (42) ( 272 The bound protein is detected by a specific biotin-labeled monoclonal 273 antibody, which is then subsequently detected by europium-labeled 274 streptavidin. The provided signal is measured by time-resolved fluorometry.
275 Four internal controls were added to each assay plate in both assays.
277

MASP-1 levels assay 278 279
The time-resolved immunofluorimetric assay for MASP-1 is an 280 inhibition assay, where circulating MASP-1 in the sample inhibits the binding 281 of an anti-MASP-1 antibody to a surface coated with a fragment of MASP-1, 
401
Linkage disequilibrium between the intron 1 and exon 12 alleles 402 resulted in a total of twelve different MASP1 haplotypes in leprosy patients 403 and thirteen in controls, among which those with frequencies higher than 10% 404 were GC_CCG, followed by GT_CCG, GC_CTG, GC_CCA and AC_CCG.
405 Three of them were associated with leprosy, independently of any other 406 demographic factor ( 466 concentrations reached lower levels, independent of the genotype (medians 467 4,557 and 4,228 ng/mL, respectively) ( Fig 3A) . 
475
Regarding the exon 12 variants, there was no association with the 476 rs72549262 variant. However, in accordance with the associated effect of the 477 intron 1 rs13064994 polymorphism, controls with the minor rs850314*A allele 478 of exon 12 presented higher MASP-3 levels, than G/G homozygotes (6,373 479 [2,286-11,820] ng/mL vs. 5,450 [2,149-11,480] ng/mL, P=0.0342). This 480 difference was no longer noticeable among patients, whose MASP-3 levels 481 were generally lower (medians 4,500-4,554 ng/mL) and seemed no longer to 482 be under the same genetic control ( Fig 3B) . In contrast, carriers of the minor 483 rs1109452*T allele presented lower MASP-3 levels in controls, although they 484 did not differ between healthy and diseased carriers ( Fig 3C) . Contrary to 485 MASP-3 levels, MASP-1 serum concentration of rs1109452*T carriers were 486 higher than in C/C homozygotes, independent of the disease (Fig 3D) .
487
The adjacent exon 12 rs1109452*C and rs850314*A, as well as Fig 4B) . 
508
Healthy individuals carrying the GT_CCG haplotype presented higher 509 MASP-3 levels than those without it (median: 6,131 [2,286-11,820] ng/mL vs.
510 5,148 [2,149-12,580] ng/mL), a difference no longer noticed among leprosy 511 patients ( Fig 5A) . Similarly, controls with the GC_CCG haplotype, but not 6) . 
571
Both pathways lead to C3b-opsonization and CR1-mediated internalization of the pathogen. There are numerous polymorphisms in the MASP1 gene that may 583 interfere with gene expression, some of which had been formerly investigated 584 by others (53) (17) . We chose to investigate two SNPs located in a regulatory 585 region of intron 1, which may interfere with the production of all three MASP1 586 proteins, and three in exon 12, which is exclusive of MASP-3 and may 587 uniquely affect the expression level of this protein. None of them had been 588 previously investigated.
589
rs7609662*A in intron 1 is associated with higher MASP1 mRNA levels 590 in several tissues (https://gtexportal.org/home/snp/rs7609662), but we did not 591 identify this effect at the protein level. The rs13064994*T had the opposite 592 effect (https://gtexportal.org/home/snp/rs13064994) on MASP1 mRNA 593 expression. We found an association of this allele with higher MASP-3 protein 594 levels, but only in healthy individuals. The absence of a clear correlation 595 between mRNA levels and protein concentration in serum is not unexpected, 596 since former analyses did not consider different MASP1 transcripts, and 597 stability of mRNA in cytoplasm may be greatly affected by regulatory 598 mechanisms that were not accounted for in previous transcriptomic 599 analyses.
664 may be regulated by noncoding polymorphisms investigated in this study.
665
Although interpreting the evidence is not straghtforward, it certainly fosters 666 more investigations on the role played by MASP1 products in the resitance 667 against mycobacterial infections and its more severe forms. In particular,
668
MASP-3 and MAp44 may be evaluated as new therapeutic agents against 669 leprosy infection and against polarization to lepromatous disease. 670 671 672
